Literature DB >> 30976852

Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus.

Chantal Kopecky1,2, Yuliya Lytvyn3, Oliver Domenig4, Marlies Antlanger5, Johannes J Kovarik5, Christopher C Kaltenecker5, Marko Poglitsch4, Bruce A Perkins6, Kerry-Anne Rye7, David Z I Cherney3, Marcus D Säemann8,9.   

Abstract

Entities:  

Keywords:  Angiotensins; Diabetes mellitus; Empagliflozin; Renin–angiotensin system activation; SGLT-2 inhibition

Mesh：

Substances：

Year:  2019        PMID： 30976852     DOI： 10.1007/s00125-019-4871-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  9 in total

1.  Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.

Authors:  Lodi C W Roksnoer; Richard van Veghel; René de Vries; Ingrid M Garrelds; Usha M Bhaggoe; Edith C H Friesema; Frank P J Leijten; Marko Poglitsch; Oliver Domenig; Marian C Clahsen-van Groningen; Ewout J Hoorn; A H Jan Danser; Wendy W Batenburg
Journal:  Kidney Int       Date:  2015-04-01       Impact factor: 10.612

2.  Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.

Authors:  David Z I Cherney; Bruce A Perkins; Nima Soleymanlou; Fengxia Xiao; Joseph Zimpelmann; Hans-Juergen Woerle; Odd E Johansen; Uli C Broedl; Maximilian von Eynatten; Kevin D Burns
Journal:  Kidney Int       Date:  2014-11       Impact factor: 10.612

3.  Guidelines for managing high blood pressure.

Authors:  Wendy S Klein; C Noel Bairey Merz; Marjorie R Jenkins
Journal:  JAMA       Date:  2014-07-16       Impact factor: 56.272

Review 4.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

Authors:  Hiddo J L Heerspink; Bruce A Perkins; David H Fitchett; Mansoor Husain; David Z I Cherney
Journal:  Circulation       Date:  2016-07-28       Impact factor: 29.690

5.  Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.

Authors:  David Z I Cherney; Bruce A Perkins; Nima Soleymanlou; Maria Maione; Vesta Lai; Alana Lee; Nora M Fagan; Hans J Woerle; Odd Erik Johansen; Uli C Broedl; Maximilian von Eynatten
Journal:  Circulation       Date:  2013-12-13       Impact factor: 29.690

6.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

7.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

Review 8.  Molecular mechanisms of diabetic kidney disease.

Authors:  Kimberly Reidy; Hyun Mi Kang; Thomas Hostetter; Katalin Susztak
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

9.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245
  9 in total
  7 in total

Review 1.  SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.

Authors:  Hongyan Liu; Vikas S Sridhar; Bruce A Perkins; Julio Rosenstock; David Z I Cherney
Journal:  Curr Diab Rep       Date:  2022-05-28       Impact factor: 4.810

2.  The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.

Authors:  Rosalie A Scholtes; Daniël H van Raalte; Ricardo Correa-Rotter; Robert D Toto; Hiddo J L Heerspink; Valerie Cain; C David Sjöström; Peter Sartipy; Bergur V Stefánsson
Journal:  Diabetes Obes Metab       Date:  2019-12-14       Impact factor: 6.577

Review 3.  Cardiorenal Protection in Diabetic Kidney Disease.

Authors:  Jason F Lee; Ecaterina Berzan; Vikas S Sridhar; Ayodele Odutayo; David Z I Cherney
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-19

4.  Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial.

Authors:  Marlies Antlanger; Oliver Domenig; Christopher C Kaltenecker; Johannes J Kovarik; Vincent Rathkolb; Martin M Müller; Elisabeth Schwaiger; Manfred Hecking; Marko Poglitsch; Marcus D Säemann; Chantal Kopecky
Journal:  Diabetes Obes Metab       Date:  2022-01-24       Impact factor: 6.408

5.  Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial.

Authors:  Janaka Karalliedde; Nikos Fountoulakis; Dimitra Stathi; Antonella Corcillo; Maria Flaquer; Angeliki Panagiotou; Giuseppe Maltese; Anastasios Mangelis; Salma Ayis; Luigi Gnudi
Journal:  Front Cardiovasc Med       Date:  2022-09-30

Review 6.  Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors.

Authors:  Dimitrios Patoulias; Christodoulos Papadopoulos; Konstantinos Stavropoulos; Ioanna Zografou; Michael Doumas; Asterios Karagiannis
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-14       Impact factor: 3.738

7.  Empagliflozin Alleviates Left Ventricle Hypertrophy in High-Fat-Fed Mice by Modulating Renin Angiotensin Pathway.

Authors:  Juliana Cordovil Cotrin; Gabriel Santos Martins de Souza; Tamiris Ingrid Petito-da-Silva; Luiz Eduardo Macedo Cardoso; Vanessa Souza-Mello; Sandra Barbosa-da-Silva
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2022-01-18       Impact factor: 1.636
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.